Realm Therapeutics PLC Presents at Wedbush PacGrow Healthcare Conference
August 08 2018 - 2:01AM
RNS Non-Regulatory
TIDMRLM
Realm Therapeutics PLC
08 August 2018
Realm Therapeutics to Present at the 2018 Wedbush PacGrow
Healthcare Conference
MALVERN, PA, August 8, 2018 - Realm Therapeutics plc (NASDAQ:RLM
/ AIM:RLM), a clinical stage biopharmaceutical company focused on
developing novel therapeutics in immune-mediated diseases,
announces today that Alex Martin, CEO, will be presenting at the
2018 Wedbush PacGrow Healthcare Conference, on Tuesday, August 14,
2018 at 4:15 p.m. ET at the Parker New York.
A live and archived webcast of the Wedbush presentation will be
available on the Events and Presentations page of the Company's
website at www.realmtx.com.
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company
developing novel therapeutics that target the interplay between
innate and adaptive immunity. The Company's programs seek to
influence immune signalling and change the course of
immune-mediated diseases in adults and children. Realm's lead drug
development program utilizes the Company's proprietary
immunomodulatory technology for the treatment of Atopic Dermatitis,
and the Company is exploring its efficacy in other dermatology
indications which include Acne Vulgaris, and Psoriasis, as well as
other therapeutic areas. For more information on Realm Therapeutics
please visit www.realmtx.com.
RNS-RLM
Contacts:
Realm Therapeutics plc
Alex Martin, Chief Executive Officer
Marella Thorell, Chief Financial Officer and Chief Operating
Officer
Outside US: +44 (0) 20 3727 1000
US: +1 212 600 1902
Argot Partners
Stephanie Marks / Claudia Styslinger
+1 212 600 1902
FTI Consulting
Simon Conway / Mo Noonan
+44 (0) 20 3727 1000
N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Jen
Boorer
+44 (0) 20 7496 3000
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGMGGRVNDGRZM
(END) Dow Jones Newswires
August 08, 2018 02:01 ET (06:01 GMT)
Puricore (LSE:PURI)
Historical Stock Chart
From Dec 2024 to Jan 2025
Puricore (LSE:PURI)
Historical Stock Chart
From Jan 2024 to Jan 2025